DE60230687D1 - Verhinderung und Behandlung von durch Androgenmangel induzierter Osteoporose - Google Patents

Verhinderung und Behandlung von durch Androgenmangel induzierter Osteoporose

Info

Publication number
DE60230687D1
DE60230687D1 DE60230687T DE60230687T DE60230687D1 DE 60230687 D1 DE60230687 D1 DE 60230687D1 DE 60230687 T DE60230687 T DE 60230687T DE 60230687 T DE60230687 T DE 60230687T DE 60230687 D1 DE60230687 D1 DE 60230687D1
Authority
DE
Germany
Prior art keywords
prevention
treatment
induced osteoporosis
androgen deficiency
androgen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60230687T
Other languages
English (en)
Inventor
Mitchell S Steiner
Sharan Raghow
Karen A Veverka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncternal Therapeutics Inc
Original Assignee
GTx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GTx Inc filed Critical GTx Inc
Application granted granted Critical
Publication of DE60230687D1 publication Critical patent/DE60230687D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60230687T 2001-11-29 2002-11-27 Verhinderung und Behandlung von durch Androgenmangel induzierter Osteoporose Expired - Lifetime DE60230687D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33373401P 2001-11-29 2001-11-29

Publications (1)

Publication Number Publication Date
DE60230687D1 true DE60230687D1 (de) 2009-02-12

Family

ID=23304031

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60226494T Expired - Lifetime DE60226494D1 (de) 2001-11-29 2002-11-27 Vorbeugung und behandlung von durch androgenmangel induzierter osteoporose
DE60230687T Expired - Lifetime DE60230687D1 (de) 2001-11-29 2002-11-27 Verhinderung und Behandlung von durch Androgenmangel induzierter Osteoporose

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60226494T Expired - Lifetime DE60226494D1 (de) 2001-11-29 2002-11-27 Vorbeugung und behandlung von durch androgenmangel induzierter osteoporose

Country Status (23)

Country Link
US (1) US6899888B2 (de)
EP (5) EP1574212A1 (de)
JP (2) JP2005515988A (de)
KR (1) KR100658110B1 (de)
CN (2) CN1679956A (de)
AT (2) ATE394099T1 (de)
AU (2) AU2002356928B2 (de)
BR (1) BR0214801A (de)
CA (2) CA2468719C (de)
CY (2) CY1108174T1 (de)
DE (2) DE60226494D1 (de)
DK (2) DK1666033T3 (de)
EA (1) EA200400744A1 (de)
ES (2) ES2305350T3 (de)
GE (1) GEP20094841B (de)
HK (2) HK1068104A1 (de)
HR (1) HRP20040547A2 (de)
IL (2) IL162144A0 (de)
MX (1) MXPA04005112A (de)
PT (2) PT1460969E (de)
SI (2) SI1666033T1 (de)
TW (1) TWI315987B (de)
WO (1) WO2003047504A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20040176470A1 (en) * 1998-05-07 2004-09-09 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US7645898B2 (en) * 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US7622503B2 (en) * 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7855229B2 (en) * 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US7524866B2 (en) * 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
US8853266B2 (en) * 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US20060019989A1 (en) * 2004-07-21 2006-01-26 Steiner Mitchell S Compositions comprising 5-alpha reductase inhibitors and SERMs and methods of use thereof
EP1786408A4 (de) * 2004-09-03 2010-07-28 Hormos Medical Ltd Verwendung eines selektiven östrogenrezeptormodulators zur herstellung eines pharmazeutischen präparates zur verwendung in einem verfahren für die behandlung oder vorbeugung von androgenmangel
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
RU2008122993A (ru) * 2005-11-09 2009-12-20 Хормос Медикал Лтд. (Fi) Препаративные формы фиспемифена
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
CA2824517A1 (en) * 2005-11-28 2007-05-31 Gtx, Inc. Nuclear receptor binding agents
US8546451B2 (en) 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8637706B2 (en) 2005-11-28 2014-01-28 Gtx, Inc. Nuclear receptor binding agents
WO2008099060A2 (en) 2007-02-14 2008-08-21 Hormos Medical Ltd Methods for the preparation of fispemifene from ospemifene
EP2821385B1 (de) 2007-02-14 2016-07-27 Hormos Medical Ltd. Verfahren zur Herstellung von therapeutisch nützlichen Triphenylbutenderivaten
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
PT2222636E (pt) 2007-12-21 2013-07-16 Ligand Pharm Inc Moduladores seletivos de recetores de andrógeno (sarms) e suas utilizações
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
IN2015DN01046A (de) 2012-07-13 2015-06-26 Gtx Inc
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9321712B2 (en) 2012-10-19 2016-04-26 Fermion Oy Process for the preparation of ospemifene
EP3613418A1 (de) 2014-01-17 2020-02-26 Ligand Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur modulierung von hormonspiegeln
ES2828305T3 (es) * 2014-07-24 2021-05-26 Aspen Park Pharmaceuticals Inc Tratamiento de sofocos y pérdida ósea inducidos por tratamiento de privación de andrógenos utilizando cis-clomifeno

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2464203A (en) 1943-05-21 1949-03-15 Boots Pure Drug Co Ltd Manufacture of dienoestrol
US2465505A (en) 1944-12-05 1949-03-29 Hoffmann La Roche Process for the manufacture of 3, 4-di-(p-hydroxy-phenyl)-hexadiene-2, 4
US2914562A (en) 1957-08-06 1959-11-24 Wm S Merrell Co Amine derivatives of triphenylethanol
GB2126576B (en) 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
US5491173A (en) 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
AU5851690A (en) * 1989-07-07 1991-02-06 Endorecherche Inc. Method of treatment of androgen-related diseases
GB9126209D0 (en) 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
GB9207437D0 (en) 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
US5468488A (en) * 1993-06-24 1995-11-21 Wahi; Ashok L. Electrostatically charged nasal application product and method
TW303299B (de) * 1993-07-22 1997-04-21 Lilly Co Eli
DE19526146A1 (de) * 1995-07-07 1997-01-09 Schering Ag Triphenylethylene, Verfahren zu deren Herstellung, diese Triphenylethylene enthaltene pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
US5859045A (en) * 1996-05-08 1999-01-12 Novo Nordisk A/S Novo Alle Crystalline -! 3R 4R-trans-7 methoxy 2,2-dimethyl1-3-phenyl 1-4 4-12 pyrrolidin-1 -Y1!ethoxyl 1!chromane hydrogen fumarate
US6632447B1 (en) 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6413533B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
WO1999056739A1 (en) 1998-05-07 1999-11-11 The University Of Tennessee Research Corporation A method for chemoprevention of prostate cancer
US6413534B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
AU3342099A (en) * 1998-06-16 2000-01-05 Pfizer Products Inc. Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty
EP1004306A3 (de) * 1998-08-06 2000-06-07 Pfizer Products Inc. Estrogen Agonisten/Antagonisten
WO2000008001A1 (en) * 1998-08-07 2000-02-17 Chiron Corporation Substituted isoxazole as estrogen receptor modulators
JP2002522380A (ja) * 1998-08-07 2002-07-23 アンドルシェルシュ・インコーポレイテッド タイプ３３α−ヒドロキシステロイドデヒドロゲナーゼの阻害
WO2000074684A1 (en) * 1999-06-04 2000-12-14 The General Hospital Corporation Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use
EP1246814B1 (de) * 1999-12-30 2005-02-16 Signal Pharmaceuticals, Inc. Verbindungen und verfahren zur modulation von estrogen rezeptoren
GB0012291D0 (en) * 2000-05-23 2000-07-12 Astrazeneca Ab Pharmaceutical combination
WO2002002099A1 (en) * 2000-07-05 2002-01-10 Astrazeneca Ab Pharmaceutical combination of an anti-androgen and tamoxifen for providing an anti-androgenic effect and aromatase inhibition

Also Published As

Publication number Publication date
JP2005515988A (ja) 2005-06-02
EP2098247A3 (de) 2010-05-26
EP1574212A1 (de) 2005-09-14
IL162144A0 (en) 2005-11-20
EP1460969A2 (de) 2004-09-29
AU2002356928B2 (en) 2008-04-17
CN1617691A (zh) 2005-05-18
WO2003047504A3 (en) 2003-10-16
AU2008203121A1 (en) 2008-08-07
DK1666033T3 (da) 2009-04-06
CA2468719C (en) 2011-05-24
CY1108895T1 (el) 2014-07-02
CN1679956A (zh) 2005-10-12
EP1862165A2 (de) 2007-12-05
CA2537913A1 (en) 2003-06-12
US6899888B2 (en) 2005-05-31
EP1460969A4 (de) 2005-08-17
KR100658110B1 (ko) 2006-12-14
DE60226494D1 (de) 2008-06-19
CA2468719A1 (en) 2003-06-12
CN100548283C (zh) 2009-10-14
CY1108174T1 (el) 2014-02-12
PT1666033E (pt) 2009-02-09
BR0214801A (pt) 2005-01-11
HK1068104A1 (en) 2005-04-22
SI1460969T1 (sl) 2008-10-31
US20030153625A1 (en) 2003-08-14
TW200410711A (en) 2004-07-01
GEP20094841B (en) 2009-11-25
ATE394099T1 (de) 2008-05-15
HK1092066A1 (en) 2007-02-02
EP1460969B1 (de) 2008-05-07
ATE418972T1 (de) 2009-01-15
TWI315987B (en) 2009-10-21
HRP20040547A2 (en) 2005-08-31
AU2002356928A1 (en) 2003-06-17
EA200400744A1 (ru) 2005-02-24
EP1666033B1 (de) 2008-12-31
EP1666033A1 (de) 2006-06-07
EP2098247A2 (de) 2009-09-09
IL206646A0 (en) 2011-07-31
EP1862165A3 (de) 2008-06-25
SI1666033T1 (sl) 2009-06-30
ES2305350T3 (es) 2008-11-01
JP2005247862A (ja) 2005-09-15
DK1460969T3 (da) 2008-09-01
MXPA04005112A (es) 2005-04-29
KR20050044618A (ko) 2005-05-12
WO2003047504A2 (en) 2003-06-12
ES2319785T3 (es) 2009-05-12
PT1460969E (pt) 2008-07-01

Similar Documents

Publication Publication Date Title
DE60230687D1 (de) Verhinderung und Behandlung von durch Androgenmangel induzierter Osteoporose
EP1446114A4 (de) Zusammensetzungen und verfahren zur behandlung von osteoporose
ATE376444T1 (de) Ibandronsäure zur behandlung und vorbeugung von osteoporose
ATE448744T1 (de) Vorrichtung zur behandlung von frakturen des femur
CY1107862T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν παραγωγα οιστερολης για χρηση στη θεραπεια του καρκινου
DE60227095D1 (de) Zusammensetzungen und verfahren zur behandlung von abgebundenem gips
IL159422A0 (en) Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
ATE414512T1 (de) Kombinationstherapie zur behandlung von krebs
ATE279208T1 (de) Verfahren und stoffe zur behandlung des prostatakarzinomes
IL158206A0 (en) Compositions and methods for the prevention and treatment of human prostate cancer
IL145397A0 (en) Compositions and methods for treatment of cancer
NO20024735D0 (no) Anvendelse av fulvestrant for behandling av resistent brystcancer
DE60223707D1 (de) Calcium-l-threonat zur behandlung von knochenfrakturen
ATE255452T1 (de) Antagonismus des estrogen-rezeptors-beta und knochenkrankheiten
DE69231403T2 (de) Reinigung einer den müller-mischtumor inhibierenden substanz und behandlung von einigen tumoren
IL160816A0 (en) Compositions and methods for treatment of cancer
DE60024450D1 (de) Modulierung der angiogenese durch verwendung von anti-angiogenischen angiotensin-7 und dafür kodierende polynukleotiden zur behandlung von tumoren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition